OTCMKTS:MLNTQ Melinta Therapeutics (MLNTQ) Stock Price, News & Analysis $0.11 0.00 (0.00%) As of 04/20/2020 Add Compare Share Share Stock Analysis Stock Analysis About Melinta Therapeutics Stock (OTCMKTS:MLNTQ) Get Melinta Therapeutics alerts:Sign Up Key Stats Today's Range$0.11▼$0.1150-Day Range$0.11▼$0.1152-Week Range$0.06▼$8.60Volume32,900 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Melinta Therapeutics is a pharmaceutical company focused on the development and commercialization of antibiotics for serious and life-threatening bacterial infections. Its products have primarily targeted hospital and acute-care settings, as well as certain community-acquired infections, with an emphasis on treating drug-resistant pathogens and addressing unmet needs in infectious disease. Melinta’s commercial portfolio has included Vabomere (meropenem and vaborbactam), an intravenous antibiotic used for certain serious infections caused by resistant bacteria; Orbactiv (oritavancin), a long-acting treatment for acute bacterial skin and skin-structure infections; Minocin for Injection (minocycline); and Baxdela (delafloxacin), an antibiotic approved for specified acute bacterial skin infections and community-acquired bacterial pneumonia. The company was founded as Rib-X Pharmaceuticals and adopted the Melinta Therapeutics name in 2013. It later underwent financial restructuring, including a Chapter 11 bankruptcy process, and continued operating as a privately held specialty pharmaceutical business. Its products and commercial activities have primarily served healthcare providers and patients in the United States, with a focus on infectious-disease treatment.AI Generated. May Contain Errors. Read More Receive MLNTQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLNTQ Stock News HeadlinesCorMedix raises 2025 revenue guidance to $390M-$410M amid accelerated Melinta integration and DefenCath momentumNovember 12, 2025 | msn.comCorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’August 8, 2025 | msn.comElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.October 16 at 1:00 AM | Brownstone Research (Ad)Melinta Therapeutics Inc (MLNTQ)April 10, 2025 | uk.investing.comMelinta Therapeutics & OptimizeRx Announce 2022 Innovate4Outcomes EventNovember 30, 2022 | yahoo.comMelinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022October 18, 2022 | benzinga.comNexus loses generic drug approval thanks to contactless FedEx deliveryOctober 10, 2022 | reuters.comRain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in LiposarcomaAugust 4, 2022 | finance.yahoo.comSee More Headlines MLNTQ Stock Analysis - Frequently Asked Questions How have MLNTQ shares performed this year? Melinta Therapeutics' stock was trading at $0.11 at the beginning of 2026. Since then, MLNTQ shares have increased by 0.0% and is now trading at $0.11. Company Calendar Today10/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:MLNTQ CIKN/A Webwww.cempra.com Phone908-617-1309FaxN/AEmployees290Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (OTCMKTS:MLNTQ) was last updated on 4/20/2020 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Melinta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Melinta Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
